Inhibition of human ether-a-go-go-related gene potassium channels by α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin
暂无分享,去创建一个
Hugo A. Katus | Y. Kuryshev | H. Katus | Dierk Thomas | E. Ficker | J. Kiehn | W. Schoels | C. Karle | Dierk Thomas | Anna-Britt Wimmer | Kezhong Wu | Johann Kiehn | Wolfgang Schoels | Anna-Britt Wimmer | Kezhong Wu | Bettina C. Hammerling | Eckhard K. Ficker | Yuri A. Kuryshev | Christoph A. Karle | Anna‐Britt Wimmer
[1] H. Katus,et al. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. , 2003, Cardiovascular research.
[2] H. Katus,et al. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[3] H. Katus,et al. Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. , 2003, Cardiovascular research.
[4] J. Mitcheson. Drug binding to HERG channels: evidence for a ‘non‐aromatic’ binding site for fluvoxamine , 2003, British journal of pharmacology.
[5] H. Katus,et al. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[6] Hugo A Katus,et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.
[7] N. Kyprianou. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. , 2003, The Journal of urology.
[8] E. Wanke,et al. Cell Cycle-dependent Expression of HERG1 and HERG1B Isoforms in Tumor Cells* , 2003, The Journal of Biological Chemistry.
[9] R. Piñeiro,et al. Doxazosin Induces Apoptosis in Cardiomyocytes Cultured In Vitro by a Mechanism That Is Independent of &agr;1-Adrenergic Blockade , 2003, Circulation.
[10] Baofeng Yang,et al. HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. , 2002, Cancer research.
[11] E. Newell,et al. Functional Up-regulation of HERG K+ Channels in Neoplastic Hematopoietic Cells* , 2002, The Journal of Biological Chemistry.
[12] Stanley Nattel,et al. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? , 2002, The Journal of physiology.
[13] Dierk Thomas,et al. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.
[14] N. Kyprianou,et al. Quinazoline-derived α1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α1-Adrenoceptor-independent Action , 2002 .
[15] E. Crawford,et al. Terazosin, doxazosin, and prazosin: current clinical experience. , 2001, Urology.
[16] T. McDonald,et al. HERG K+ Channel Activity Is Regulated by Changes in Phosphatidyl Inositol 4,5-Bisphosphate , 2001, Circulation research.
[17] A. Brown,et al. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. , 2001, The Journal of pharmacology and experimental therapeutics.
[18] S. Kathöfer,et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. , 2001, Cardiovascular research.
[19] E. Wanke,et al. HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium , 2000, British Journal of Cancer.
[20] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[21] N. Kyprianou,et al. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. , 2000, Cancer research.
[22] P. Kang,et al. Apoptosis and heart failure: A critical review of the literature. , 2000, Circulation research.
[23] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[24] John S. Mitcheson,et al. Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.
[25] M. Jiang,et al. Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.
[26] S. Viskin. Long QT syndromes and torsade de pointes , 1999, The Lancet.
[27] W. Kübler,et al. Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A* , 1999, The Journal of Biological Chemistry.
[28] C. January,et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.
[29] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[30] W. Kübler,et al. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[31] M. Gaffney,et al. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. , 1999, Urology.
[32] M. Lazdunski,et al. HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. , 1998, Molecular pharmacology.
[33] L. Bianchi,et al. herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? , 1998, Cancer research.
[34] W. Wonderlin,et al. Potassium Channels, Proliferation and G1 Progression , 1996, The Journal of Membrane Biology.
[35] Pool Jl,et al. DOXAZOSIN: A NEW APPROACH TO HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA , 1996, The British journal of clinical practice.
[36] R. Ruffolo,et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. , 1996, The Journal of pharmacology and experimental therapeutics.
[37] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[38] J. Warmke,et al. A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] R. Grimm,et al. alpha 1-antagonists in the treatment of hypertension. , 1989, Hypertension.
[40] S. Umemura,et al. Antihypertensive Effects and Pharmacokinetics of Single and Consecutive Administration of Doxazosin in Patients with Mild to Moderate Essential Hypertension , 1987, Journal of cardiovascular pharmacology.
[41] P. Meredith,et al. Pharmacokinetic overview of doxazosin. , 1987, The American journal of cardiology.
[42] R. Sonders. Pharmacokinetics of terazosin. , 1986, The American journal of medicine.
[43] S. E. Patterson. Terazosin kinetics after oral and intravenous doses , 1985, Clinical pharmacology and therapeutics.
[44] B. Sakmann,et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.
[45] D. Shen,et al. Alpha adrenoceptor blockade with oral prazosin , 1981, Clinical pharmacology and therapeutics.
[46] M. Safar,et al. Clinical Pharmacology of Prazosin in Hypertensive Patients with Chronic Renal Failure , 1981, Journal of cardiovascular pharmacology.
[47] P. Jaillon. Clinical Pharmacokinetics of Prazosin , 1980, Clinical pharmacokinetics.
[48] M. Michel,et al. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. , 1998, British journal of clinical pharmacology.